Investigating Denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules – 2 × 2 factorial design (GeparX)

Mapping Intimacies ◽

10.1055/s-0038-1651752 ◽

2018 ◽

Author(s):

S Kümmel ◽

G Minckwitz ◽

V Vladimirova ◽

V Nekljudova ◽

P Wimberger ◽

...

Keyword(s):

Breast Cancer ◽

Factorial Design ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment

Download Full-text

Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps635 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS635-TPS635 ◽

Author(s):

Sherko Kümmel ◽

Gunter Von Minckwitz ◽

Valentina Nekljudova ◽

Serban Dan Costa ◽

Carsten Denkert ◽

...

Keyword(s):

Breast Cancer ◽

Factorial Design ◽

Hormone Receptor ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment

Download Full-text

Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)—An iterim safety analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.569 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 569-569 ◽

Author(s):

Sherko Kummel ◽

Pauline Wimberger ◽

Gunter Von Minckwitz ◽

Valentina Nekljudova ◽

Carsten Denkert ◽

...

Keyword(s):

Breast Cancer ◽

Factorial Design ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment ◽

Safety Analysis

Download Full-text

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)

PLoS ONE ◽

10.1371/journal.pone.0143643 ◽

2015 ◽

Vol 10 (12) ◽

pp. e0143643 ◽

Author(s):

Yoshie Hasegawa ◽

Hirokazu Tanino ◽

Jun Horiguchi ◽

Daishu Miura ◽

Takashi Ishikawa ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trial ◽

Zoledronic Acid ◽

Primary Breast Cancer ◽

Controlled Trial ◽

Neoadjuvant Treatment ◽

Randomized Controlled

Download Full-text

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

Breast Cancer ◽

10.1007/s12282-018-0839-7 ◽

2018 ◽

Vol 25 (4) ◽

pp. 407-415 ◽

Author(s):

N. Masuda ◽

M. Toi ◽

N. Yamamoto ◽

H. Iwata ◽

K. Kuroi ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Therapy ◽

Primary Breast Cancer ◽

Prolonged Exposure ◽

Phase Ii Trial ◽

Neoadjuvant Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label Phase

Download Full-text

Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.537 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 537-537 ◽

Author(s):

M. Dowsett ◽

I. E. Smith

Keyword(s):

Breast Cancer ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment ◽

Molecular Effects ◽

Download Full-text

Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.537 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 537-537

Author(s):

M. Dowsett ◽

I. E. Smith

Keyword(s):

Breast Cancer ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment ◽

Molecular Effects ◽

Download Full-text

Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2007.07.002 ◽

2008 ◽

Vol 66 (1) ◽

pp. 31-41 ◽

Author(s):

George Lazaridis ◽

George Pentheroudakis ◽

Nicholas Pavlidis

Keyword(s):

Breast Cancer ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment

Download Full-text

Abstract PD3-7: Disease-free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer (JONIE-1 study)

10.1158/0008-5472.sabcs13-pd3-7 ◽

2013 ◽

Author(s):

D Miura ◽

Y Hasegawa ◽

J Horiguchi ◽

T Ishikawa ◽

M Hayashi ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trial ◽

Zoledronic Acid ◽

Primary Breast Cancer ◽

Controlled Trial ◽

Neoadjuvant Treatment ◽

Disease Free Survival ◽

Free Survival ◽

Randomized Controlled ◽

Download Full-text

Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70313-6 ◽

2008 ◽

Vol 6 (7) ◽

pp. 47 ◽

Author(s):

M. Untch ◽

M. Rezai ◽

S. Loibl ◽

P.A. Fasching ◽

J. Huober ◽

...

Keyword(s):

Breast Cancer ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment ◽

Efficacy And Safety

Download Full-text

Results of Neoteam: A randomized multicenter phase II study of liposomal doxorubicin hydrochloride + trastuzumab vs conventional doxorubicin both in combination with cyclophosphamide and followed by docetaxel + trastuzumab as neoadjuvant treatment of HER2-positive primary breast cancer

Annals of Oncology ◽

10.1093/annonc/mdw365.72 ◽

2016 ◽

Vol 27 ◽

pp. vi91

Author(s):

S. Pernas Simon ◽

M. Rezai ◽

M. Hauschild ◽

J.P. Machiels ◽

S. Paepke ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Primary Breast Cancer ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Neoadjuvant Treatment ◽

Doxorubicin Hydrochloride ◽

Her2 Positive ◽

Multicenter Phase

Download Full-text